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Multi-vessel diseaseBackground: The recently published COMPLETE trial has demonstrated that patients with ST-segment
elevation myocardial infarction (STEMI) and multivessel coronary artery disease (MVD), who underwent
successful percutaneous coronary intervention (PCI) of both culprit and non-culprit (vs. culprit-only)
lesions had a reduced risk of major adverse cardiac events (MACE), but not of cardiovascular or total mor-
tality. The aim of this meta-analysis was to assess the efficacy of complete revascularization on cardio-
vascular or total mortality reduction using available randomized controlled trials (RCTs) including the
COMPLETE trial, in hemodynamically stable STEMI patients with MVD.
Methods: PubMed, MEDLINE, Embase, Scopus, Google Scholar, CENTRAL and ClinicalTrials.gov databases
search identified 10 RCTs of 7033 patients with STEMI and MVD which compared complete (n = 3420) vs.
only culprit lesion (n = 3613) PCI for a median 27.7 months follow-up. Random effect risk ratios were
used to estimate for efficacy and safety outcomes.
Results: Complete revascularization reduced the risk of MACE (10.4% vs.16.6%; RR = 0.59, 95% CI: 0.47 to
0.74, p < 0.0001), CV mortality (2.87% vs. 3.72%; RR = 0.73, 95% CI: 0.56 to 0.95, p = 0.02), reinfarction (5.1%
vs. 7.1%; RR = 0.67, 95% CI: 0.52 to 0.86, p = 0.002), urgent revascularization (7.92% vs.17.4%; RR = 0.47,
95% CI: 0.30 to 0.73, p < 0.001), and CV hospitalization (8.68% vs.11.4%; RR = 0.65, 95% CI: 0.44to 0.96,
p = 0.03) compared with culprit only revascularization. All-cause mortality, stroke, major bleeding events,
or contrast induced nephropathy were not affected by the revascularization strategy.
Conclusion: The findings of this meta-analysis suggest that in patients with STEMI and MVD, complete
revascularization is superior to culprit-only PCI in reducing the risk of MACE outcomes, including cardio-
vascular mortality, without increasing the risk of adverse safety outcomes.
 2020 Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Primary percutaneous coronary intervention (PCI) is the treat-
ment of choice of patients with ST-segment elevation myocardialinfarction (STEMI) [1–3]. Approximately half of those patients have
multivessel disease (MVD) [4], who carry worse clinical outcome
after primary PCI compared with those with single vessel coronary
artery disease (CAD) [5,6]. The standard treatment for hemody-
namically stable patients with STEMI and MVD is primary PCI of
the culprit lesion that aims at early myocardial reperfusion [7,8].
Historic randomized controlled trials (RCTs) [9–11] influenced
the American College of Cardiology/American Heart Association
(ACC/AHA) to update their guidelines recommendation class from
III to IIb for the PCI of the non-culprit in hemodynamically stable
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(FFR)-guided PCI of non-culprit lesions in patients with MVD
resulted in decreased composite cardiovascular (CV) adverse
events, compared with only culprit lesion PCI, thus offering new
evidence on the value of complete revascularization (CR) in STEMI
[13]. These findings prompted the European Society of Cardiology
(ESC) to upgrade its guidelines to the recommendation class IIa
[2]. However, these trials were limited by their relatively small
sample sizes, and it remained uncertain if endpoints other than
revascularization were reduced. The recently published COMPLETE
trial [14], which included more patients than all previous RCTs
combined, confirmed the findings of the previous trials. Moreover,
it showed that CR of stable STEMI patients with MVD reduced the
risk of all cardiac events including the composite of cardiovascular
death and myocardial infarction, with a significant reduction in
spontaneous myocardial infarction. However, it is still uncertain
whether there is a significant reduction in cardiovascular and total
death.
Therefore, we conducted this meta-analysis of randomized clin-
ical trials to assess the efficacy of CR compared with PCI of only
culprit lesion in lowering the risk of cardiovascular and total
deaths in patients with STEMI and MVD.2. Methods
We followed the guidelines of the 2009 preferred reporting
items for systematic reviews and meta-analysis (PRISMA) state-
ment [15]. Due to the study design (meta-analysis), neither Institu-
tional Review Board (IRB) approval nor patient informed consent
was needed.Fig. 1. PRISMA study seThis meta-analysis was registered on PROSPERO, with
number CRD42020149697.
2.1. Search strategy
We systematically searched PubMed-Medline, EMBASE, Scopus,
Google Scholar, the Cochrane Central Registry of Controlled Trials
and ClinicalTrial.gov, up to September 2019, using the following
key words: ‘‘percutaneous coronary intervention” OR ‘‘PCI” AND
‘‘myocardial infarction” OR ‘‘ST elevation myocardial infarction”
OR ‘‘STEMI” OR ‘‘multi vessel” AND ‘‘Culprit artery” OR ‘‘target ves-
sel revascularization” OR ‘‘infarct related artery revascularization”
OR ‘‘non-culprit artery” OR ‘‘complete”. Additional searches for
potential trials included the references of review articles on that
issue, and the abstracts from selected congresses: scientific ses-
sions of the European Society of Cardiology (ESC), the American
Heart Association (AHA), American College of Cardiology (ACC)
and European Society of Atherosclerosis (EAS). The wild-card term
‘‘*’’ was used to increase the sensitivity of the search strategy. The
literature search was limited to articles published in English. Two
reviewers (IB and HJ) independently evaluated each article sepa-
rately. No filters were applied. The remaining articles were
obtained in full-text and assessed again by the same two research-
ers who evaluated each article independently, carried out data
extraction and quality assessment. Disagreements were resolved
by discussion with a third party (GB).
2.2. Eligibility criteria
Selected studies had to fulfill the following criteria: (i) Studies
with hemodynamically stable STEMI patients with low clinicallection flow chart.
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and culprit only revascularization; and (iii) Outcome data at
follow-up. None of the studies evaluated in this meta-analysis
included hemodynamically unstable patients complicated with
heart failure or shock.2.3. Data extraction
Eligible studies were reviewed and the following data were
abstracted: (1) first author’s name; (2) year of publication; (3)
name of clinical trial; (4) country where the study was performed;
(5) number of centers; (6) study design; (7) number of participants
in the two groups of STEMI revascularization and (8) clinical data
of interest as well as number of events with respect to clinical out-
comes were extracted.Fig. 2. Risk ratios of outcome with complete revascularization versus culprit-o2.4. Outcomes and definitions
The primary outcomes tested were major adverse cardiac
events (MACE), which were considered as per-study definition,
all-cause mortality, cardiac mortality, non-fatal myocardial infarc-
tion, revascularization, stroke, contrast induced nephropathy and
major bleeding (Supplementary Table 1). Complete revasculariza-
tion was defined as revascularization of non-culprit lesions in
STEMI patients, either during the same procedure or staged during
index hospitalization or after discharge. Only culprit lesion revas-
cularization was defined as PCI of the only infarct related artery.
2.5. Quality assessment
Assessment of risk of bias in the included studies was evaluated
by the same investigators for each study and was performed sys-nly revascularization; (a) MACE; (b) All-cause mortality; (c) CV mortality.
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[16]. The Cochrane tool has 7 criteria for quality assessment: ran-
dom sequence generation (selection bias), allocation sequence con-
cealment (selection bias), blinding of participants and personnel
(performance bias), blinding of outcome assessment (detection
bias), incomplete outcome data (attrition bias), selective outcome
reporting (reporting bias) and other potential sources of bias. The
risk of bias in each study was classified as ‘‘low”, ‘‘high” or
‘‘unclear”.2.6. Statistical analysis
The meta-analysis was performed using the RevMan (Review
Manager [RevMan] Version 5.1, The Cochrane Collaboration,
Copenhagen, Denmark), with two-tailed p value < 0.05 considered
as significant [17]. The baseline characteristics are reported as
median and range. Mean and standard deviation (SD) values were
estimated using the method described by Hozo et al [18]. The anal-
ysis is presented in forest plots. Meta-analyses were performed
with a fixed-effects model and a random effect model was used
if heterogeneity was encountered. Heterogeneity between studies
was assessed using Cochrane Q test and I2 index. As a guide,
I2 < 25% indicated low, 25–50% moderate and > 50% high hetero-Fig. 3. Risk ratios of outcome with complete revascularization versus culprit-only revgeneity [19]. Based on value of hazard ratio when it is 1, above
or below we calculated the risk relative risk for CV events [20].
Publication bias was assessed using visual inspection of funnel
plots and Egger’s test.3. Results
3.1. Search results and trial flow
Of 2895 articles identified in the initial searches, 659 studies
were screened as potentially relevant, but following critical scru-
tiny only 10 RCTs [9–11,13,14,21–25] deemed appropriate for
inclusion (Fig. 1). Three studies which compared complete revas-
cularization at staged procedure vs. indexed procedure were also
excluded having failed the preset definition of randomization
[26–28]. FFR was systematically used to stratify patients with
MVD only in two studies [11,24].
3.2. Characteristics of included studies
The ten qualified studies had a total of 7033 patients, 3420 in
the CR group and 3613 in the culprit-only revascularization group.
The duration of the follow-up ranged from 4 to 38 months (medianascularization; (a) Reinfarction; (b) Urgent revascularization; (c) Hospitalization.
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24% diabetes, 40.4% arterial hypertension, 34.6% dyslipidemia and
51.2% smokers (Supplementary Table 1).3.3. Clinical outcomes
MACE was reported in all trials, but its definition differed
among studies (Supplementary Table 2). In comparison to
culprit-only, the CR strategy was associated with lower risk for
MACE (10.4% vs.16.6%; RR = 0.59, 95% CI: 0.47 to 0.74,
p < 0.0001, I2 = 61%, Fig. 2a) and CV mortality (2.87% vs. 3.72%;
RR = 0.73, 95% CI: 0.56 to 0.95, p = 0.02, I2 = 0%, Fig. 2c). Whereas
the risk of all-cause mortality (4.58% vs. 5.04%; RR = 0.87, 95% CI:
0.70 to 1.07, p = 0.18, I2 = 0%, Fig. 2b) did not differ between groups.
A meta-regression analysis showed that follow-up was associated
with higher MACE in the two group of revascularization (p = 0.04
for both), all-cause mortality (p < 0.001 and p = 0.03, respectively)
and CV mortality (p < 0.001 for both, Supplementary Fig. 1).
Furthermore, the other clinical outcome measures including
reinfarction (5.1% vs. 7.1%; RR = 0.67, 95% CI: 0.52 to 0.86,
p = 0.002, I2 = 10%, Fig. 3a), urgent revascularization (7.92%
vs.17.4%; RR = 0.40, 95% CI: 0.25 to 0.66, p < 0.001, I2 = 81%) and
CV hospitalization (8.68% vs.11.4%; RR = 0.65, 95% CI: 0.44 to
0.96, p = 0.03, I2 = 0%) were higher in the culprit-only group com-
pared with the CR group (Fig. 3b & c). There was no evidence for
publication bias according to the Egger’s test used, for any of the
outcomes assessed. Clinical outcomes of the meta analysis are
summarized in Supplementary Fig. 2.Fig. 4. Risk ratios of safety procedure with complete revascularization versus culprit-o
nephropathy.3.4. Safety outcomes
Complete revascularization was associated with similar risk of
stroke (1.52% vs.1.23%; RR = 0.98, 95% CI: 0.38 to 2.49, p = 0.96,
I2 = 24%), major bleeding events (2.42% vs.1.81%; RR = 1.28, 95%
CI: 0.89 to 1.84, p = 0.18, I2 = 0%) and contrast induced nephropathy
(1.62% vs.1.11%; RR = 1.49, 95% CI: 0.91 to 2.46, p = 0.12, I2 = 0%,
Fig. 4a-c) to culprit-only revascularization. There was no evidence
for publication of bias with Egger’s test for any of the outcomes
assessed.3.5. Influence analysis
The influence analysis was not performed as a classic leave-one-
out analysis but only by excluding the COMPLETE trial. Exclusion of
the COMPLETE trial, which represented more than 50% of the study
population did not change the results of our analysis, Fig. 5, Sup-
plementary Figs. 3-4).3.6. Risk of bias assessment
The assessment of risk of bias and applicability concerns based
on the Quality Assessment of Diagnostic Accuracy Studies ques-
tionnaire (QUADAS-2) was used on our study questions (Supple-
mentary Table 3) [15]. All of the criteria domains for risk of bias
and applicability were analyzed. The risk of bias was assessed as
‘‘low risk,’’ ‘‘high risk,’’ or ‘‘unclear risk’’. Most studies had high
quality (high or moderate level) and clearly defined objectivesnly revascularization; (a) Stroke; (b) Major bleeding events; (c) Contrast induced
Fig. 5. Risk ratios of outcome with complete revascularization versus culprit-only revascularization with the exclusion of COMPLETE trial 2019; (a) MACE; (b) All-cause
mortality; (c) CV mortality.
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Fig. 5). All domains had low risk of bias (<20%), and no evidence for
publication bias based on the Egger’s test.4. Discussion
This meta-analysis of RCTs compared the efficacy and safety of
CR versus a culprit-only PCI strategy in hemodynamically stable
patients with STEMI. The main findings can be summarized as fol-
lows: (1) CR is associated with a significant reduction in the risk for
MACE over a median of 27.7 months (range 38–42 months). This
benefit is derived from significant reduction in re-infarction and
the need for urgent revascularization and hospitalization; (2) CR
significantly reduced CV mortality, when compared with culprit-
only revascularization strategy; and (3) CR is safe in this group ofstable patients with regards to procedure related stroke,
contrast-induced nephropathy and major bleeding events.
The previous evidence for CR of patients with STEMI and MVD
in hemodynamically stable patients, based on which the current
guidelines recommendation class IIb (ACC/AHA) [12] and IIa
(ESC) [2] is limited. On the other hand, the COMPLETE trial with
its larger number of patients provided a stronger evidence support-
ing CR over and above culprit-only revascularization for such
patients. CR resulted in reduced risk for the composite of CV death
or recurrent myocardial infarction during the follow-up period
[14]. However, this benefit was driven mainly by a reduction in
myocardial infarction, since CV mortality and all-cause mortality
were not significantly different between groups.
The pooled analysis of all data from included RCTs [9–11,13,1
4,21–25] found a significant difference between the CR strategy
and culprit only strategy on all-cause mortality. It should be appre-
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and above culprit-only revascularization was not clear from the
older data [9–11,13,14,21–23]. Older trials and meta analyses did
not support an additional benefit from CR, probably because of dif-
ferent inclusion criteria of patients and studies as well as different
means for measuring clinical outcome [29–37]. We believe that the
results of the current meta analysis are of clinical relevance based
on reduced MACE at mid-term follow up which is what concerns
most patients. Apart from the cost, our analysis did not show any
significant difference in the other potential CR related complica-
tions when compared with culprit only revascularization, thus
supporting the CR approach. Finally, the extra cost itself should
be assessed in comparison with the cost of readmission and
myocardial infarction, which might result in significant irreversible
myocardial loss.
In view of the findings of this meta-analysis and the discussion
above we anticipate that the current clinical guidelines should
benefit from advancing the recommendation for CR in stable STEMI
patients as a routine strategy when it is feasible. In this line, a
recent meta-analysis of the revascularization strategy in patients
with STEMI and multivessel disease [38] demonstrated a reduction
of CV mortality in patients who underwent complete revascular-
ization. This meta-analysis, assessed by inverse variance, included
6 RCTs and was focused on CV mortality as the main outcome. The
CV mortality reduction in favor of complete revascularization
strategy in this meta-analysis was less significant compared with
our results. Moreover, we included 10 RCTs, including the updated
CvLPRIT (with follow-up 3.6 years). Thus, our results are support-
ive of the previously published meta-analysis [38].4.1. Limitations
Like most meta-analyses of RCTs based on systematic search of
the published literature, ourmeta-analysis is also subject to several
limitations. This is a study-level meta analysis and therefore we
could not adjust our results for several patient characteristics that
might influence the study outcomes. Lack of sufficient data to per-
form subgroup analyses of the different outcome between the two
strategies of complete revascularization strategy, index vs. staged
procedure, is another limitation. We consider that the time when
CR is performed may be important in line with previous suggestion
of 72 h [39]. We were not able to use the hazard ratio to measure
the effect of CR procedure, due to considerable heterogeneity in the
follow-up duration. The safety outcome was not reported in all tri-
als. Although most of the RCTs had high quality and all domain had
low risk of bias, there was a moderate degree of heterogeneity in
MACE and urgent revascularization. Also, not all RCTs included
all assessed outcomes. Finally, the definition of non-culprit signif-
icant stenosis, using angiographic or functional criteria, was
heterogeneous in the included RCTs. However, recent meta-
analysis that compared the two different approaches [40] sug-
gested the need of dedicated prospective studies that will directly
compare angiography with physiology-guided CR strategy in
STEMI patients.5. Conclusion
The current meta-analysis demonstrates that the risk of MACE,
CV mortality, reinfarction, need for urgent revascularization and
hospitalization for patients with STEMI and multi-vessel disease
undergoing primary PCI are reduced by complete revascularization
compared with the culprit-only coronary artery strategy. PCI
related complications were not different between the two
strategies.Appendix A. Supplementary material
Supplementary data to this article can be found online at
https://doi.org/10.1016/j.ijcha.2020.100549.
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